A team led by psychiatrist Richard Lyus and researcher Florian Naudet published an analysis in Cochrane Evidence Synthesis and Methods arguing that a 2006 Iranian trial of 40 children had data flaws serious enough to undermine its reliability. They say this single study has disproportionately influenced clinical guidelines recommending fluoxetine (Prozac) for depression in children and adolescents, though they are not calling for doctors to stop prescribing it.
nature.com
· 2026-10-02
Late-stage clinical trial results published in the New England Journal of Medicine show patients on the highest dose of retatrutide lost an average of 25% of body weight after 80 weeks, rising to 30% after 104 weeks. More than a third of participants lost 30% or more of their weight, and the drug also improved knee osteoarthritis pain, sleep apnea symptoms, and cardiometabolic markers including blood pressure and cholesterol.
arstechnica.com
· 2026-09-29
Researchers report interim results from the ongoing Algonquin study, a multicentre, open-label trial evaluating a BPd drug combination in patients with relapsed or refractory multiple myeloma. The analysis covers patients enrolled in the trial's second phase, with data collected through late October 2025 after enrollment closed in September 2022. Eligible patients had failed prior treatments including lenalidomide and proteasome inhibitors, but had not previously received pomalidomide or BCMA-targeted therapy.
nature.com
· 2026-09-16
Researchers gave ten older women with severe osteoporosis a single infusion of their own bone-marrow cells, which had been lab-modified to better home in on bone tissue. Before the treatment the women fractured bones roughly every one to two years; afterward, low-impact fractures dropped to about once per decade, according to a study published in Cell.
nature.com
· 2026-09-11
The FDA has cleared daraxonrasib, a new drug for pancreatic cancer, after a large clinical trial found patients on the treatment survived roughly twice as long as those receiving standard chemotherapy. The approval gives doctors a new option for a disease long known for poor treatment outcomes.
gizmodo.com
· 2026-08-26
GoKawiil